PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/519,427		
INFORMATION DISCLOSURE				Filing Date	December 22, 2004		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	BIANCHI, Marco		
(Use as many sheets as necessary)				Art Unit	1646		
(Use as many sneeds as necessary)				Examiner Name	Bruce D. Hissong, Ph.D.		
Sheet	1	of	1	Attorney Docket Number	1014-PCT-US		

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	PCT International Search Report for BIANCHI, et al., Int'l Application No. PCT/IT2003/000265, Filed April 29, 2003, Dated November 13, 2003.	
	11	YANG HUAN, et al.; "HMGB1 as a Cytokine Therapeutic Target", Journal of Education Research, Vol. 8, No. 6, October 3, 2002, Pages 469-472, XP009020930.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.